BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17975017)

  • 1. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results.
    Adès L; Sanz MA; Chevret S; Montesinos P; Chevallier P; Raffoux E; Vellenga E; Guerci A; Pigneux A; Huguet F; Rayon C; Stoppa AM; de la Serna J; Cahn JY; Meyer-Monard S; Pabst T; Thomas X; de Botton S; Parody R; Bergua J; Lamy T; Vekhoff A; Negri S; Ifrah N; Dombret H; Ferrant A; Bron D; Degos L; Fenaux P
    Blood; 2008 Feb; 111(3):1078-84. PubMed ID: 17975017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.
    Adès L; Chevret S; Raffoux E; de Botton S; Guerci A; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Maloisel F; Deconinck E; Ferrant A; Thomas X; Fegueux N; Chomienne C; Dombret H; Degos L; Fenaux P;
    J Clin Oncol; 2006 Dec; 24(36):5703-10. PubMed ID: 17116939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
    Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
    Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
    Fenaux P; Chastang C; Chevret S; Sanz M; Dombret H; Archimbaud E; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Makhoul PC; Travade P; Solary E; Fegueux N; Bordessoule D; Miguel JS; Link H; Desablens B; Stamatoullas A; Deconinck E; Maloisel F; Castaigne S; Preudhomme C; Degos L
    Blood; 1999 Aug; 94(4):1192-200. PubMed ID: 10438706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
    Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
    Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients.
    Adès L; Chevret S; Raffoux E; Guerci-Bresler A; Pigneux A; Vey N; Lamy T; Huguet F; Vekhoff A; Lambert JF; Lioure B; de Botton S; Deconinck E; Ferrant A; Thomas X; Quesnel B; Cassinat B; Chomienne C; Dombret H; Degos L; Fenaux P;
    Am J Hematol; 2013 Jul; 88(7):556-9. PubMed ID: 23564205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
    Tallman MS; Kim HT; Montesinos P; Appelbaum FR; de la Serna J; Bennett JM; Deben G; Bloomfield CD; Gonzalez J; Feusner JH; Gonzalez M; Gallagher R; Miguel JD; Larson RA; Milone G; Paietta E; Rayon C; Rowe JM; Rivas C; Schiffer CA; Vellenga E; Shepherd L; Slack JL; Wiernik PH; Willman CL; Sanz MA
    Blood; 2010 Dec; 116(25):5650-9. PubMed ID: 20858857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
    Martínez-Cuadrón D; Montesinos P; Vellenga E; Bernal T; Salamero O; Holowiecka A; Brunet S; Gil C; Benavente C; Ribera JM; Pérez-Encinas M; De la Serna J; Esteve J; Rubio V; González-Campos J; Escoda L; Amutio ME; Arnan M; Arias J; Negri S; Lowënberg B; Sanz MA
    Leukemia; 2018 Jan; 32(1):21-29. PubMed ID: 28584252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
    Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
    J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
    Lengfelder E; Görlich D; Nowak D; Spiekermann K; Haferlach C; Krug U; Kreuzer KA; Braess J; Schliemann C; Lindemann HW; Horst HA; Schiel X; Flasshove M; Hecht A; Schnittger S; Schneider S; Wörmann B; Hofmann WK; Berdel WE; Bormann E; Sauerland C; Büchner T; Hiddemann W;
    Eur J Haematol; 2018 Feb; 100(2):154-162. PubMed ID: 29114972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute promyelocytic leukemia by retinoids.
    Fenaux P; Wang ZZ; Degos L
    Curr Top Microbiol Immunol; 2007; 313():101-28. PubMed ID: 17217041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
    Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
    J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group.
    Fenaux P; Chastang C; Degos L
    Leukemia; 1994; 8 Suppl 2():S42-7. PubMed ID: 7815836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute promyelocytic leukemia: results of the Chilean protocol LPA2000].
    Undurraga MS; Puga B; Cabrera ME; Palma T; Rossle A; Vergara CG; Rojas B; Aspillaga A
    Rev Med Chil; 2013 Oct; 141(10):1231-9. PubMed ID: 24522350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
    Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
    Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
    Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
    Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
    Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
    Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.